BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SciLifeLab - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SciLifeLab
X-ORIGINAL-URL:https://www.scilifelab.se
X-WR-CALDESC:Events for SciLifeLab
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20251205T101500
DTEND;TZID=Europe/Stockholm:20251205T110000
DTSTAMP:20260602T152023
CREATED:20251120T134320Z
LAST-MODIFIED:20251120T140035Z
UID:191272-1764929700-1764932400@www.scilifelab.se
SUMMARY:Discovery and developmentof GRK2-biased beta 2-adrenergic receptor agonists for the treatment of metabolic disorders
DESCRIPTION:Presenter: Dr Benjamin Pelcman\, Atrogi AB \n\n\n\nAtrogi AB is biotech company pioneering first-in-class treatments to revolutionize metabolic health. The talk will describe how targeting a novel GRK-biased b2-adrenergic receptor signaling pathway allows for the successful design of compounds useful in the treatment of disorders like type 2 diabetes (T2D)\, obesity and muscular wasting. The approach will be exemplified by the invention\, selection and development of ATR-258\, a b2-AR agonist that was developed for T2D and is about to enter phase 2 clinical trials. During the exploration of the chemical space\, a diverse set of molecules were synthesized\, and their effect on the downstream signaling will be discussed. In addition\, the seminar will illustrate differences between drug development in Big Pharma and small biotech and the challenges of working in an environment with limited resources. \n\n\n\nAfter receiving his Ph.D. in Organic Chemistry at KTH and a post doc session at Dartmouth College\, NH\, USA\, Benjamin joined Astra Pain Control\, first in Södertälje and then in Montreal\, as a medicinal chemist. Benjamin has also held various positions at Pharmacia & Upjohn\, Karo Bio\, Biolipox and Orexo. After having started his own consultancy company\, BeePCo\, he came in contact with Atrogi where he was employed first as a CEO and later as Head of Chemistry and IP. Benjamin is now retired but is still working as a consultant for Atrogi and other small biotechs.
URL:https://www.scilifelab.se/event/discovery-and-developmentof-grk2-biased-beta-2-adrenergic-receptor-agonists-for-the-treatment-of-metabolic-disorders/
LOCATION:BMC Room C4:301\, Husargatan 3\, entrance C1\, Uppsala\, Sweden
CATEGORIES:Event
END:VEVENT
END:VCALENDAR